4T1	Mouse breast cancer cells
9-AC	9-Aminocamptothecin
9-CPT	Rubitecan
9-NC	9-Nitrocamptothecin
A2780sn	Human ovarian cancer cell line
A549	Human lung carcinoma cell line
ALL	Acute lymphocytic leukemia
AML	Acute myelogenous leukemia
AUC	Area under the curve
BAX	Bcl-2-associated X protein
BEL-7402	Human hepatoma cell line
Caco-2	Colorectal adenocarcinoma cell line
CD123	Interleukin-3 receptor alpha chain
CD147 mAb	CD147 monoclonal antibody
CKD-602	Belotecan
CL	ε-Caprolactone
Cmax	Highest concentration of the drug
COLO-205	Human colon carcinoma cell line
CPPs	Cell penetrating peptides
CPT	Camptothecin
CPT-11	Irinotecan
CT26	Mouse colorectal carcinoma cell line
CuAAC	Cu(I)-catalyzed azidealkyne cycloaddition
Da	Dalton
DDSs	Drug delivery systems
DX-8951f	Exatecan
EE	Entrapment efficiency
EGDMA	Ethylene glycol dimethacrylate
FDA	US Food and Drug Administration
FGF3	Fibroblast growth factor 3 gene
FOL	Folate
GG-211	Lurtotecan
GSH	Glutathione
GA	Glycolide monomer
H22	Hepatocellular carcinoma cell line
HCT116	Human colon cancer cell line
Hep3B	Human hepatoma cell line
HepG2	Human hepatocellular carcinoma cells
HGC27	Gastric cancer cells
HGG	High-grade glioma
HIST	Histone cluster 1 gene
HMW	High molecular weight
HT-29	Human colorectal adenocarcinoma cell culture
IC50	Drug concentration needed to inhibit 50% of the cell growth
IRH LA	Irinotecan hydrochloride trihydrate Lactide monomer
LMW	Low molecular weight
mAB	Monoclonal antibodies
MC3T3	Mouse osteoblast cell line
Mn	Number-averaged molecular weight
Mw	Weight-averaged molecular weight
mPEG	Monomethoxy-poly(ethylene glycol)
MPEG-P(CL-ran-TMC)	Monomethyl poly(ethylene glycol)-poly-(ε-caprolactone)-poly(trimethylene carbonate)
mPEG-PLA	Methoxypoly(ethylene glycol)-b-poly(lactide)
MRT	Mean residence time
MTD	Maximum tolerated dose
MX-1	Human mammary carcinoma cell line
NPs	Nanoparticles
NX-211	Liposomal lurtotecan
OSI-211	Liposomal lurtotecan
OVCAR 3	Human ovarian carcinoma cell line
P(EAEP-PPA)	Poly(ethyl-bis(2-(acryloxy)ethyl phosphate-co-2-propynylamine)
Panc-1	Human pancreatic cancer cell line
PARP	Poly adenosine diphosphate-ribose polymerase
PBS	Phosphate buffer solution
PCL	Poly(ε-caprolactone)
PDCs	Polymer–drug conjugates
PDLLA	Poly(D,L-lactide)
PEG	Poly(ethylene glycol)
PGA	Poly(glycolide), Poly(glycolic acid)
PGACL	Poly(glycolide-co-ε-caprolactone)
PHB	Poly(3-hydroxybutyrate)
PHF	Poly(1-hydroxymethylethylene hydroxy-methyl formal)
PLA	Polylactide
PLACL	Poly(lactide-co-ε-caprolactone)
PLGA	Poly(lactide-co-glycolide)
PDLA	Poly(D-lactide)
PLLA	Poly(L-lactide)
rac-LA	A racemic mixture of L-LA and D-LA
RAFT	Reversible addition fragmentation transfer
RGCC	Regulator of cell cycle, response gene to complement 32 protein
ROMP	Ring-opening metathesis polymerization
ROP	Ring-opening polymerization
S-180	Sarcoma bearing Kunming mice
SAR	Structure–activity relationship
sc-PLA	Stereocomplex PLA
SKOV3	Human ovarian cancer cell line
SMPs	SN-38-loaded biodegradable PLGA microparticles
SN-38	7-Ethyl-10-hydroxycamptothecin
SN-38-BOC	7-Ethyl-10-O-tert-butyl ester-camptothecin
SW-480	Human colon adenocarcinoma cell line
SW1990	Human pancreatic cell line
SW620	Human colon tumor
TGI	Tumor growth inhibition
THP-1	Human acute myeloid leukemia cell line
Tmax	Time to reach maximum concentration of the drug
TMC	Trimethylene carbonate
TMC	N-Trimethyl chitosan chloride
Top 1	Topoisomerase I
UBD	Ubiquitin D gene
UV	Ultraviolet
Vss	Volume of distribution at steady stage
WBC	White blood cell
ζ	Zeta potential